Model Organisms in Drug Discovery

248 CHEMICAL MUTAGENESIS IN THE MOUSE
Graw, J., Neuhauser-Klaus, A. and Pretsch, W. (1997). Detection of a point mutation (A
to G) in exon 5 of the murine Mgf gene defines a novel allele at the Steel locus with a
weak phenotype. Mutat. Res. 382, 75–78.
Graw, J., Jung, M., Loster, J., Klopp, N., Soewarto, D., Fella, C., Fuchs, H., et al. (1999).
Mutation in the betaA3/A1-crystallin encoding gene Cryba1 causes a dominant cataract
in the mouse. Genomics 62, 67–73.
Graw, J., Klopp, N., Neuhauser-Klaus, A., Favor, J. and Loster, J. (2002a). Crygf(Rop):
the first mutation in the Crygf gene causing a unique radial lens opacity. Invest
Ophthalmol. Vis. Sci. 43, 2998–3002.
Graw, J., Neuhauser-Klaus, A., Loster, J., Klopp, N. and Favor, J. (2002b).
Ethylnitrosourea-induced base pair substitution affects splicing of the mouse gammaE-
Crystallin encoding gene leading to the expression of a hybrid protein and to a cataract.
Genetics 161, 1633–1640.
Gunther, T., Sporle, R. and Schughart, K. (1997). The open brain (opb) mutation maps to
mouse chromosome 1. Mamm. Genome 8, 583–585.
Harris, S. (2001). Transgenic knockouts as part of high-throughput, evidence-based target
selection and validation strategies. Drug Discov. Today 6, 628–636.
Harris, S. and Foord, S. M. (2000). Transgenic gene knock-outs: functional genomics and
therapeutic target selection. Pharmacogenomics 1, 433–443.
Hartwell, L. H., Culotti, J., Pringle, J. R. and Reid, B. J. (1974). Genetic control of the cell
division cycle in yeast. Science 183, 46–51.
Hentges, K., Thompson, K. and Peterson, A. (1999). The flat-top gene is required for
the expansion and regionalization of the telencephalic primordium. Development 126,
1601–1609.
Hentges, K. E., Sirry, B., Gingeras, A. C., Sarbassov, D., Sonenberg, N., Sabatini, D. and
Peterson, A. S. (2001). FRAP/mTOR is required for proliferation and patterning during
embryonic development in the mouse. Proc. Natl. Acad. Sci. USA 98, 13 796–13 801.
Herron, B. J., Lu, W., Rao, C., Liu, S., Peters, H., Bronson, R. T., Justice, M. J., et al.
(2002). Efficient generation and mapping of recessive developmental mutations using
ENU mutagenesis. Nat. Genet. 30, 185–189.
Hitotsumachi, S., Carpenter, D. A. and Russell, W. L. (1985). Dose-repetition increases the
mutagenic effectiveness of N-ethyl-N-nitrosourea in mouse spermatogonia. Proc. Natl.
Acad. Sci. USA 82, 6619–6621.
Hrabe de Angelis, M. H. and Balling, R. (1998). Large scale ENU screens in the mouse:
genetics meets genomics. Mutat. Res. 400, 25–32.
Hrabe de Angelis, M. H., Flaswinkel, H., Fuchs, H., Rathkolb, B., Soewarto, D.,
Marschall, S., Heffner, S., et al. (2000). Genome-wide, large-scale production of mutant
mice by ENU mutagenesis. Nat. Genet. 25, 444–447.
Huszar, D., Lynch, C. A., Fairchild-Huntress, V., Dunmore, J. H., Fang, Q., Berkemeier,
L. R., Gu, W., et al. (1997). Targeted disruption of the melanocortin-4 receptor results in
obesity in mice. Cell 88, 131–141.
Justice, M. J. (2000). Capitalizing on large-scale mouse mutagenesis screens. Nat. Rev.
Genet. 1, 109–115.
Justice, M. J., Noveroske, J. K., Weber, J. S., Zheng, B. and Bradley, A. (1999). Mouse
ENU mutagenesis. Hum. Mol. Genet. 8, 1955–1963.
Justice, M. J., Carpenter, D. A., Favor, J., Neuhauser-Klaus, A., Hrabe de Angelis, M. H.,
Soewarto, D., Moser, A., et al. (2000). Effects of ENU dosage on mouse strains. Mamm.
Genome 11, 484–488.